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Specific molecular targeting 
of renal injury in obstructive 
nephropathy
RL Chevalier1
Progression of most renal disease involves tubulointerstitial injury, 
characterized by tubular atrophy, inflammatory cell infiltration, 
and interstitial fibrosis. Transforming growth factor-β1 is central in 
this process. As reported by Moon et al., molecular targeting of the 
transforming growth factor-β1 signaling pathway can markedly 
suppress renal injury resulting from unilateral ureteral obstruction, 
an established model of obstructive nephropathy. Specific kinase 
inhibitors are promising therapeutic agents to slow or attenuate 
progressive renal fibrosis.
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It has become increasingly apparent that 
renal interstitial fi brosis represents a fi nal 
common pathway for most forms of chron-
ically progressive renal disorders. Much 
attention has therefore focused on the cel-
lular and molecular mechanisms underly-
ing these disorders, with the ultimate aim 
of preventing or attenuating the progressive 
loss of renal parenchyma. Most progressive 
renal disease in adults is initiated by vascu-
lar and glomerular pathology (hyperten-
sion and diabetes), whereas in children, 
congenital renal maldevelopment pre-
dominates (with obstructive nephropathy 
comprising the greatest identifi able frac-
tion). Chronic unilateral ureteral obstruc-
tion (UUO) has emerged as a highly useful 
model for unraveling the intricacies of pro-
gressive renal interstitial fi brosis. Following 
UUO, renal tubular cell injury results from 
mechanical stretching, ischemia, hypoxia, 
or exposure to toxins such as oxygen free 
radicals, and the renal tubular epithelial 
cell either undergoes cell death by apop-
tosis or necrosis, or undergoes phenotypic 
transformation, acquiring mesenchymal 
characteristics1 (Figure 1). If the stimulus 
is transient, these changes can lead either 
to remodeling or to regeneration of the 
tubular epithelium. If the insult is severe or 
prolonged, however, a maladaptive 
response is activated, resulting in the 
attraction to the interstitium of infl am-
matory cells (particularly macrophages) 
that further damage the tubules and lead 
to increased deposition of extracellular 
matrix (Figure 1). Th us, three cell types 
appear to play vital roles in the progres-
sion of interstitial renal fi brosis: tubular 
epithelial cells, infi ltrating or proliferating 
infl ammatory cells, and interstitial fi brob-
lasts2 (Figure 1).
In the past decade, a variety of cell sig-
naling pathways have been elucidated, 
revealing overlapping regulation of cell 
death, inflammation, and fibrosis. The 
intrarenal renin-angiotensin system has 
emerged as a central player in this scheme, 
as angiotensin II modulates inflamma-
tion and cell death in addition to regulat-
ing interstitial fi brosis.3 For these reasons, 
angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers are 
increasing used clinically to slow or attenu-
ate the progression of renal disorders and 
proteinuria. Although angiotensin activates 
a broad spectrum of injurious cell signaling 
pathways, its stimulation of transforming 
growth factor beta (TGF-β1) appears to 
play a dominant role. Indeed, TGF-β1 has 
emerged as the quintessential fi brogenic 
cytokine that also acts as a proinfl amma-
tory and proapoptotic molecule (Figure 
1). Th us, administration of neutralizing 
TGF-β1 antibodies, or retrograde ureteral 
injection of fi broblasts containing anti-
sense oligodeoxynucleotides for TGF-β1, 
reduces progressive renal fi brosis result-
ing from UUO.2 Th e biology of TGF-β1 
signaling has been intensely investigated: 
it is now recognized that epithelial-
mesenchymal transition of tubular cells 
as well as the stimulation of extracellular 
matrix production are enhanced by the 
TGF-β1-regulated phosphorylation of 
Smad2 and Smad3. Smads are intracellu-
lar signalling proteins that participate in 
transcriptional activation of target genes. 
In contrast to Smad2 and Smad3, Smad7 
or hepatocyte growth factor have opposing 
actions and inhibit renal fi brosis induced 
by UUO.2
In this issue of Kidney International, 
Kim et al. have taken a novel approach 
by developing IN-1130, an inhibitor of 
activin receptor-like kinase (ALK) 5 that 
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specifically inhibits Smad3 phosphor-
ylation.4 They show convincingly that 
administration of this molecule to rats 
with chronic UUO signifi cantly reduces 
the interstitial infi ltration of macrophages, 
fi broblasts, and myofi broblasts as well as 
decreasing mRNA for TGF-β1 and phos-
pho-Smad2. Th e marked response to ALK5 
inhibition may be due in part to the eff ects 
of UUO in suppressing renal production of 
SnoN and Ski (transcriptional co-repres-
sors of fibrogenic Smad2 and Smad3).5 
Although the eff ects of IN-1130 are highly 
signifi cant, there is relatively less inhibition 
aft er 14 days compared to 7 days of UUO. 
Th is is not surprising, as a number of stud-
ies of experimental UUO in mutant mice 
have shown decreasing eff ects of targeted 
deletion of fibrogenic molecules when 
the duration of obstruction is prolonged: 
alternate pathways are activated and con-
tribute to progression.6 Th is suggests that 
additional pathways contribute to the evo-
lution of renal interstitial fi brosis, and that 
treatment with combinations of agents will 
be needed to optimize therapy. Th ere is 
experimental evidence for this approach.7
Th e strategy of administering a small 
ALK5 inhibitor such as IN-1130 is made 
more attractive by the possibility of orally 
active preparations. Although a number of 
potential antifi brotic gene therapies have 
been proposed to treat UUO, there are sig-
nifi cant obstacles to this approach. Th ese 
include the ineffi  ciency of gene transfer, 
the large size of the genes of interest, and 
the short duration of expression following 
gene transfer.8 A challenge with any tar-
geted therapy for renal interstitial fi brosis 
remains the complexity of the kidney itself: 
a molecule with a salutary eff ect in one 
renal compartment may have a deleterious 
eff ect in another. A glycoprotein involved 
in the inflammatory respone, CD44 is 
upregulated in the injured kidney. Th us, 
chronic UUO has been shown to increase 
the expression of CD44 in renal tubular 
cells and protect them from apoptosis by 
acting as a survival factor.9 However, acti-
vation of CD44 also stimulates interstitial 
macrophages and aggravates interstitial 
fi brosis. In contrast, death-associate pro-
tein kinase, also upregulated in tubular 
cells following UUO, contributes to tubu-
lar apoptosis but inhibits interstitial fi bro-
blast activation.10
A final additional word of caution: 
much is being learned regarding cell sign-
aling in the kidney using rodent models of 
human renal disease. However, although 
epidermal growth factor acts as a survival 
factor and reduces interstitial fi brosis fol-
lowing chronic UUO in neonatal rats,11 
administration of epidermal growth fac-
tor to mice with UUO aggravates renal 
apoptosis and the renal lesions.12 Before 
moving to clinical trials, it will be critical 
to confi rm in man the signaling pathways 
being modulated in rodent studies. How-
ever, the development of highly specifi c 
targeted molecules, such as angiotensin 
receptor blockers, has led to major ther-
apeutic advances. Th ere is no reason to 
doubt that with the emergence of such 
targeted therapies, the treatment of renal 
fi brosis is entering a new era.
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Figure 1 | Scheme showing major cellular pathways leading to progressive renal injury 
following chronic unilateral ureteral obstruction (UUO). A complex hemodynamic and 
mechanical renal response leads to stretching of tubular cells and to localized areas of ischemia, 
hypoxia, and the generation of reactive oxygen species, all of which contribute to tubular cell 
injury. In response, tubular cells generate increased angiotensin II, which contributes to interstitial 
accumulation of macrophages, both of which contribute to the activation of TGF-β1, with subsequent 
recruitment of ALK5 and phosphorylation of the downstream signaling molecules Smad2 and 
Smad3. Phosphorylated Smad2/3, in turn, complexes with Smad4 and regulates nuclear transcription 
of genes playing a central role in progressive renal injury. The effects of activated TGF-β1 on injured 
tubular cells include the induction of apoptosis or epithelial-mesenchymal transition, with cells 
undergoing transformation to interstitial fibroblasts. Tubular apoptosis leads to tubular atrophy, 
whereas continued TGF-β1 stimulation of interstitial fibroblasts causes them to transform into 
myofibroblasts that in turn release fibrogenic cytokines, increasing extracellular matrix deposition.
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